

AMICUS THERAPEUTICS INC  
Form 8-K  
November 03, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 28, 2009**

**AMICUS THERAPEUTICS, INC.**  
(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other Jurisdiction of Incorporation)	<b>001-33497</b> (Commission File Number)	<b>71-0869350</b> (IRS Employer Identification No.)
----------------------------------------------------------------------	----------------------------------------------	--------------------------------------------------------

<b>6 Cedar Brook Drive, Cranbury, NJ</b> (Address of Principal Executive Offices)	<b>08512</b> (Zip Code)
--------------------------------------------------------------------------------------	----------------------------

Registrant's telephone number, including area code: **(609) 662-2000**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d) On October 28, 2009, Margaret G. McGlynn, R.Ph. was elected to the Board of Directors of Amicus Therapeutics, Inc. (the Company). Ms. McGlynn will join the Board of Directors as an independent director. Ms. McGlynn has not yet been appointed to any Board committees.

There is no arrangement or understanding between Ms. McGlynn and any other person pursuant to which Ms. McGlynn was elected as director of the Company. There are no relationships or transactions in which Ms. McGlynn has or will have an interest, or was or is a party, requiring disclosure under Item 404(a) of Regulation S-K.

A copy of the press release announcing Ms. McGlynn's election is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Press Release, dated November 3, 2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMICUS THERAPEUTICS, INC.

Date: November 3, 2009

By: /s/ GEOFFREY P. GILMORE

Name: Geoffrey P. Gilmore

Title: Senior Vice President and General  
Counsel

**EXHIBIT INDEX**

Exhibit No.	Description
99.1	Press Release, dated November 3, 2009